Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $4.49 -1.32%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.55, $0.03 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $173.7 million versus the consensus estimate of $184.1 million.
GUIDANCE:
Emergent BioSolutions sees FY2018 EPS of $770.00-$800.00, versus the consensus of $741.00.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
